Breaking News

U.S. Government Commits up to $1.74 Billion for mRNA COVID-19 Boosters

July 29, 2022 • 8:15 am CDT
by Tumisu
(Precision Vaccinations)

Massachusetts-based Moderna, Inc. today announced that the U.S. government had secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222.

The contract includes an award of up to $1.74 billion for the manufacture and delivery of 66 million doses of mRNA-1273.222, as well as options to purchase up to an additional 234 million doses of COVID-19 vaccine booster candidates from Moderna.

mRNA-1273.222 is a bivalent booster candidate containing the Spikevax™ vaccine plus the Omicron BA.4/5 strain mRNA.

"We are pleased to extend our successful collaboration with the U.S. government," stated Stéphane Bancel, CEO of Moderna, in a press release issued on July 29, 2022.

"Moderna's mRNA platform is enabling us to rapidly create mRNA-1273.222, a bivalent vaccine that specifically targets Omicron subvariants BA.4 and BA.5, the most prevalent variants of concern in the U.S. today."

"We remain fully committed to leveraging our innovative technology platform to offer tailored vaccines that help protect communities against COVID-19."

On July 11, 2022, Moderna announced that it is advancing two bivalent candidates for fall 2022 based on different population health security strategies in different countries.

mRNA-1273.222 contains the BA.4/5 Omicron strain and is being developed in accordance with recent FDA recommendations.

While mRNA-1273.214 contains the BA.1 Omicron strain, which may be of benefit as noted by the WHO. 

These updated bivalent vaccines, if authorized, may offer higher, broader, and more durable protection against COVID-19 says the Company.

Note: This media statement was manually curated for mobile readers.

Share